Week Adjourned: 12.9.11

A wrap-up of the week’s top class action lawsuits and lawsuit settlements, for the week ending December 9, 2011.

Top Class Actions

Seems Green Mountain may have been Roasting More Than Coffee. The company got hit with a securities class action lawsuit this week alleging it has been cooking the books.

The class action is brought against GMCR, certain of its officers and directors, and the underwriters of the Offering for violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. GMCR, based in Waterbury, Vermont, is a leader in the specialty coffee and coffee maker businesses.

FYI—GMCR produces coffee, tea and hot cocoa from its family of brands, including Tully’s Coffee(R), and manufactures the popular Keurig single-cup brewing systems that use “K-Cup” portion packs.

The lawsuit alleges that, during the Class Period, certain defendants systematically and strategically manipulated GMCR’s revenues. To do so, defendants used one of GMCR’s key fulfillment vendors, M. Block & Sons (“MBlock”), as a captive warehouse to harbor expired, excessively manufactured, or otherwise unsold product. Pursuant to the fraudulent scheme, GMCR improperly booked revenues associated with falsified sales orders for hundreds of millions of dollars in K-Cup and Keurig Brewer products, which resulted in the material overstatement of the Company’s profits, inventory, and product demand levels. GMCR also fraudulently overstated its assets in proportion to its fictitious revenues by carrying the proceeds of phantom sales as assets on its balance sheet throughout the Class Period.

On October 17, 2011, David Einhorn, a prominent activist investor, released a comprehensive report, including witness testimonials by former GMCR and MBlock employees, disclosing GMCR’s misconduct and questionable relationship with MBlock. Following the release of the report, the price of GMCR shares fell approximately 10% from its closing price of $92.09 on October 14, 2011 to close at $82.50 on October 17, 2011, the next trading day, on unusually heavy trading volume.

On October 19, 2011, after Einhorn’s presentation was more widely distributed, the price of GMCR common stock fell another 15% to close at $69.80 on October 19, 2011, on unusually heavy trading volume.

Finally, on November 9, 2011, GMCR announced disappointing earnings results and skyrocketing inventory. On this news, GMCR shares dropped 40%, from a close of $67.02 on November 9 to a close of $40.89 on November 10, 2011, on extremely heavy trading volume.

The securities lawsuit has been brought on behalf of purchasers of the common stock of Green Mountain Coffee Roasters, Inc. (“GMCR” or the “Company”) between February 2, 2011 and November 9, 2011, inclusive (the “Class Period”), including purchasers of GMCR’s common stock pursuant and/or traceable to the Company’s public offering on or around May 5, 2011 (the “Offering”).

Top Settlements

HRT Breast Cancer Settlement. This one was all over the news this week. Three women who filed lawsuits against Wyeth Pharmaceuticals and Pharmacia Upjohn alleging that their diagnoses of breast cancer were directly attributable to their use of Hormone Replacement Therapy (HRT) drugs, were awarded $72.6 million by a jury in Philadelphia hearing their consolidated lawsuit. The jury awarded $20 million to Ms. Elfont, $27.85 million to Ms. Kalenkoski and $24.75 million to Ms. Mulderig, according to the plaintiffs’ attorneys.

The three women filed individual lawsuits in July 2004 against Wyeth Pharmaceuticals and Pharmacia Upjohn, both of which have since been acquired by Pfizer.

The back story, in brief, is that Elfont, 66, had taken hormone therapy drugs for over two years before being diagnosed with breast cancer in 1997. Sixty-eight year old Kalenkoski was diagnosed with breast cancer in 2002, having taken Prempro for over four years, while Mulderig, also 68, took Premarin and Provera for 11 years before she received her breast cancer diagnosis, the PennRecord reported. It’s tragic and shocking.

According to a Bloomberg News report, Pfizer’s Wyeth and Upjohn units have lost 10 out of the 18 hormone therapy cases against them in civil court trials since 2006. Earlier this year Pfizer announced it had settled a third of the pending Prempro cases, it had set aside $772 for related claims, Bloomberg reported.

Another Bank Biggie this WeekBank of America (BofA) agreed a $315 million settlement in a securities fraud class action lawsuit that alleged the bank was misled about mortgage-backed investments sold by its Merrill Lynch unit. The settlement needs court approval in order to fly–and guess who’s making that decision? US District Judge Jed Rakoff–so all bets are off that this one get’s approved…

The Public Employees’ Retirement System of Mississippi pension fund led the lawsuit, alleging that the investments contained questionable subprime mortgages written by lenders Countrywide Financial Corp., First Franklin Financial, and IndyMac Bancorp – IndyMac went under in 2008.

Ok – That’s enough for this week. See you at the bar.

Week Adjourned: 2.11.11

Top Class Actions

Proctor & Gamble in a fix over Fixodent—they got hit with a class action lawsuit this week over allegations that their product caused the plaintiffs neurological illness

According to an investigative report by ABC News, the two lead plaintiffs, Mark Jacoby of New York and Anne Coffman of Maine, are both wheelchair bound as a result of being exposed to high levels of the mineral zinc—also known as zinc poisoning. Zinc poisoning interferes with the ability of the body to absorb copper. Both Jacoby and Coffman, and their respective physicians reportedly believe that their health problems are a result of the zinc found in Fixodent.

Just in case zinc poisoning is news to you—a paper published in Neurology in 2008 showed that “Denture cream contains zinc, and chronic excessive use may result in hypocupremia and serious neurologic disease.” In 2009, Proctor & Gamble updated the warning label on Fixodent stating that “prolonged zinc intake may be linked to adverse health effects.” 

Just as an fyi—products linked to the denture cream poisoning also include PoliGrip, and Super PoliGrip. 

Top Settlements

Bet Pfizer had some hot flashes this week. The maker of the hormone replacement therapy (HRT) Prempro, agreed to pay $330 million this week, to resolve claims that the menopause drug caused breast cancer. The settlement brings to an end eight years of litigation including some 2,200 related Prempro lawsuits that alleged Wyeth, the company that developed Prempro and was subsequently bought out by Pfizer, knew of the cancer risk but was not forthcoming about it.

According to Bloomberg, over 6 million women used Prempro and other related menopause medications to treat symptoms such as mood swings and hot flashes. Then, in 2002, results from a large cohort study, The Women’s Health Initiative, showed a link to cancer.

Pfizer reportedly faced over 10,000 lawsuits alleging that Prempro caused breast cancer in its users. The company has settled many of them in the past five months, Bloomberg reports. Those settlements include “8,000 cases consolidated in federal court in Arkansas and other cases in state courts in Pennsylvania, Nevada and Minnesota.”

BofA over its limit on overdraft fees. A federal lawsuit alleging that America’s largest bank charged excessive overdraft fees looks likely to be settled. BofA reportedly states in a recent court filing that it has reached a memorandum of understanding to settle the claims in the suit by paying $410 million. Isn’t that really just giving the money back to the people it was gouged from in the first place? That is, if the settlement is approved in court.

The suit is one of several filed against several banks from plaintiffs in 14 states, which were consolidated in a federal court in Florida. Other banks named in related suits include Wells Fargo and Citibank.

Be interesting to see how this plays out.

In the meantime—I’ll see you at the bar—coz that’s it for this week.

Week Adjourned: 11.27.09

Stork drop-down side cribs recalled; new class action filedTop Class Actions

Well, it certainly didn’t take long—48 hours maybe—after a US/Canada recall of over 2 million Stork Craft drop side cribs was issued that a class action lawsuit was filed.

Filed on behalf of all US and Canadian consumers who purchased baby cribs manufactured by Stork Craft Manufacturing, the lawsuit is seeking financial compensation for the owners of those cribs.

The recall was big news, not simply because of the number of cribs recalled, but sadly, and more importantly because of the incidents reported to the CPSC and Health Canada that prompted the recall. Specifically, 4 deaths by suffocation in the US and numerous serious falls—110 incidents in total. 

Important to note—the Stork Craft cribs may have been sold under various brand names such as Fisher-Price. Other defendants named in the suit include Sears Canada, and both the US and Canadian arms of Fisher-Price and Wal-Mart. Toys R Us is named as a defendant in Quebec.

Top Settlements

Breast Cancer Victims win Big Against Hormone Replacement Therapy Maker

Two women who each filed a lawsuit against pharmaceutical companies that make hormone replacement therapy (HRT) have both won their cases with awards of $34 million to one and $78 million to the other.

On November 20, Donna Kendall was awarded over $6 million in compensatory damages Continue reading “Week Adjourned: 11.27.09”